VG 204
Alternative Names: VG-204Latest Information Update: 07 Jul 2022
At a glance
- Originator Virogin Biotech
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; Interleukin 15 receptor alpha expression stimulants; Interleukin-12 expression stimulants; Interleukin-15 expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 07 Jul 2022 Early research in Solid tumours in Canada (Intratumoural) (Virogin Biotech pipeline, July 2022)
- 07 Jul 2022 Early research in Solid tumours in Canada (IV) (Virogin Biotech pipeline, July 2022)
- 10 Feb 2021 VG 204 is available for licensing as of 10 Feb 2021. https://virogin.com/pipeline